Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (26) 26
oncology (19) 19
humans (13) 13
female (11) 11
aged (9) 9
cancer (9) 9
chemotherapy (9) 9
middle aged (8) 8
male (7) 7
prognosis (6) 6
survival (6) 6
analysis (5) 5
care and treatment (5) 5
medicine & public health (5) 5
patients (5) 5
adult (4) 4
article (4) 4
medical research (4) 4
metastasis (4) 4
mutations (4) 4
patient outcomes (4) 4
radiotherapy (4) 4
research (4) 4
surgery (4) 4
tumors (4) 4
abridged index medicus (3) 3
adenocarcinoma (3) 3
blockade (3) 3
breast cancer (3) 3
cancer therapies (3) 3
colorectal cancer (3) 3
gemcitabine (3) 3
impact (3) 3
medical prognosis (3) 3
medicine, experimental (3) 3
neoplasm staging (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
outcomes (3) 3
recurrence (3) 3
risk (3) 3
risk factors (3) 3
survival rate (3) 3
therapy (3) 3
usage (3) 3
acquired-resistance (2) 2
activation (2) 2
aged, 80 and over (2) 2
animals (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
biochemistry & molecular biology (2) 2
biopsy (2) 2
breast-cancer patients (2) 2
carcinoma, pancreatic ductal - surgery (2) 2
cardiovascular diseases - epidemiology (2) 2
care (2) 2
chemoradiation (2) 2
clinical trials (2) 2
clinical-trials (2) 2
colorectal neoplasms - genetics (2) 2
colorectal-cancer (2) 2
communication (2) 2
comorbidity (2) 2
comorbidity index (2) 2
complications (2) 2
diagnosis (2) 2
drug dosages (2) 2
drug therapy (2) 2
epidemiology (2) 2
esophageal (2) 2
evolution (2) 2
fluorouracil (2) 2
fluorouracil - therapeutic use (2) 2
gastrointestinal cancer (2) 2
genomic landscape (2) 2
health care sciences & services (2) 2
health-related quality of life (2) 2
healthy days (2) 2
heterogeneity (2) 2
inhibition (2) 2
kaplan-meier estimate (2) 2
leucovorin - therapeutic use (2) 2
liver cancer (2) 2
liver neoplasms - secondary (2) 2
medicine, general & internal (2) 2
metastases (2) 2
mortality (2) 2
neoadjuvant therapy (2) 2
original (2) 2
original research (2) 2
pancreatic cancer (2) 2
pancreatic neoplasms - pathology (2) 2
pancreatic neoplasms - surgery (2) 2
radiation (2) 2
resection (2) 2
retrospective studies (2) 2
satisfaction (2) 2
squamous-cell carcinoma (2) 2
studies (2) 2
surgical oncology (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The Unintentional Perpetuation of the Gender Divide
by Parikh, Aparna R and Asch, David A and Armstrong, Katrina
Journal of General Internal Medicine, ISSN 0884-8734, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer
by Yaeger, R and Kotani, D and Mondaca, S and Parikh, AR and Bando, H and Van Seventer, EE and Taniguchi, H and Zhao, HY and Thant, CN and de Stanchina, E and Rosen, N and Corcoran, RB and Yoshino, T and Yao, Z and Ebi, H
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 12/2019, Volume 25, Issue 23, pp. 7089 - 7097
Purpose: While mutations in BRAF in metastatic colorectal cancer (mCRC) most commonly occur at the V600 amino acid, with the advent of next-generation... 
COLON-CANCER | CETUXIMAB | GENOMIC LANDSCAPE | ACTIVATION | INHIBITION | PREDICTIVE BIOMARKER | ONCOLOGY | SENSITIVITY | KRAS WILD-TYPE | MUTATIONS | CHEMOTHERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text MAVERICC, a randomized, biomarker-stratified, phase II study of mFOLFOX6-Bevacizumab versus FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer
by Parikh, Aparna R and Lee, Fa-Chyi and Yau, Linda and Koh, Han and Knost, James and Mitchell, Edith P and Bosanac, Ivan and Choong, Nicholas and Scappaticci, Frank and Mancao, Christoph and Lenz, Heinz-Josef
Clinical Cancer Research, ISSN 1078-0432, 2019, Volume 25, Issue 10, pp. 2988 - 2995
MAVERICC compared the efficacy and safety of modified leucovorin/5-fluorouracil/oxaliplatin plus bevacizumab (mFOLFOX6-BV) with... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
by Mitra, Devarati and Horick, Nora K and Brackett, Diane G and Mouw, Kent W and Hornick, Jason L and Ferrone, Soldano and Hong, Theodore S and Mamon, Harvey and Clark, Jeffrey W and Parikh, Aparna R and Allen, Jill N and Ryan, David P and Ting, David T and Deshpande, Vikram and Wo, Jennifer Y
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e275 - e283
Background This study characterizes the tumor‐immune microenvironment in pretreatment, localized anal squamous cell carcinoma (ASCC), including two markers... 
Immune microenvironment | Anal cancer | Chemoradiation | Indoleamine 2,3 dioxygenase 1 | Outcomes | SURVIVAL | COLOSTOMY FAILURE | INDOLEAMINE 2,3-DIOXYGENASE EXPRESSION | 3 dioxygenase 1 | HUMAN-PAPILLOMAVIRUS | CHEMOTHERAPY | Indoleamine 2 | TUMOR-INFILTRATING LYMPHOCYTES | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | NIVOLUMAB | T-CELLS | Gastrointestinal Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Enrichment of HER2 Amplification in Brain Metastases from Primary Gastrointestinal Malignancies
by Mitra, Devarati and Clark, Jeffrey W and Shih, Helen A and Oh, Kevin S and Brastianos, Priscilla K and Wo, Jennifer Y and Strickland, Matthew R and Curry, William T and Parikh, Aparna R and Corcoran, Ryan B and Ryan, David P and Iafrate, A. John and Borger, Darrell R and Lennerz, Jochen K and Hong, Theodore S
The Oncologist, ISSN 1083-7159, 02/2019, Volume 24, Issue 2, pp. 193 - 201
Background In nongastric gastrointestinal (GI) cancers, HER2‐positive (HER2+) disease is not common. In breast cancer, HER2 status is associated with increased... 
Biomarker | Brain metastases | HER2 | Gastrointestinal cancer | GASTROESOPHAGEAL ADENOCARCINOMA | PROGNOSTIC-FACTORS | ESOPHAGEAL | LAPATINIB | OVEREXPRESSION | THERAPY | ONCOLOGY | BREAST-CANCER PATIENTS | GENOMIC CHARACTERIZATION | CARCINOMA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Pencil Beam Scanning Proton Beam Chemoradiation Therapy With 5-Fluorouracil and Mitomycin-C for Definitive Treatment of Carcinoma of the Anal Canal: A Multi-institutional Pilot Feasibility Study
by Wo, Jennifer Y and Plastaras, John P and Metz, James M and Jiang, Wenqing and Yeap, Beow Y and Drapek, Lorraine C and Adams, Judith and Baglini, Christian and Ryan, David P and Murphy, Janet E and Parikh, Aparna R and Allen, Jill N and Clark, Jeffrey W and Blaszkowsky, Lawrence S and DeLaney, Thomas F and Ben-Josef, Edgar and Hong, Theodore S
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 09/2019, Volume 105, Issue 1, pp. 90 - 95
Definitive chemoradiation with concurrent 5-fluorouracil (5-FU)/mitomycin C (MMC) is an effective treatment for localized anal cancer, but it is associated... 
SURVIVAL | TRIAL | MODULATED RADIATION-THERAPY | CISPLATIN | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RADIOTHERAPY | CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Medical research | Squamous cell carcinoma | Care and treatment | Mitomycin | Dermatology | Radiation | Dermatologic agents | Radiotherapy | Analysis | Formulae, receipts, prescriptions | Medicine, Experimental | Drug therapy | Fluorouracil | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Fast-TRKing drug development for rare molecular targets
by Parikh, Aparna R and Corcoran, Ryan B
Cancer Discovery, ISSN 2159-8274, 09/2017, Volume 7, Issue 9, pp. 934 - 936
Drug development for rare molecular targets in oncology presents unique challenges. In this issue of Cancer Discovery, Drilon and colleagues report the... 
ACQUIRED-RESISTANCE | TRIALS | MUTATIONS | ONCOLOGY | CANCER | INHIBITOR ENTRECTINIB
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub‐Saharan Africa
by Fish, Madeleine and Parkes, Jeannette and Dharsee, Nazima and Dryden‐Peterson, Scott and Efstathiou, Jason and Schnipper, Lowell and Chabner, Bruce A and Parikh, Aparna R
The Oncologist, ISSN 1083-7159, 12/2019, Volume 24, Issue 12, pp. 1557 - 1561
Background Sub‐Saharan Africa is simultaneously facing a rising incidence of cancer and a dearth of medical professionals because of insufficient training... 
Medical education | Global oncology | Capacity building
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Genomic landscape of cell-free DNA in patients with colorectal cancer
by Strickler, John H and Loree, Jonathan M and Ahronian, Leanne G and Parikh, Aparna R and Niedzwiecki, Donna and Pereira, Allan Andresson Lima and McKinney, Matthew and Michael Korn, W and Atreya, Chloe E and Banks, Kimberly C and Nagy, Rebecca J and Meric-Bernstam, Funda and Lanman, Richard B and Talasaz, AmirAli and Tsigelny, Igor F and Corcoran, Ryan B and Kopetz, Scott
Cancer Discovery, ISSN 2159-8274, 02/2018, Volume 8, Issue 2, pp. 164 - 173
"Liquid biopsy" approaches analyzing cell-free DNA (cfDNA) from the blood of patients with cancer are increasingly utilized in clinical practice. However, it... 
TARGETED THERAPY | KRAS MUTATIONS | HETEROGENEITY | EGFR MONOCLONAL-ANTIBODIES | EVOLUTION | ONCOLOGY | CLONAL HEMATOPOIESIS | ACQUIRED-RESISTANCE | EXTRACELLULAR DOMAIN | BLOCKADE | CETUXIMAB RESISTANCE | Cell-free DNA | colorectal cancer | circulating tumor DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
by Parikh, AR and Leshchiner, I and Elagina, L and Goyal, L and Levovitz, C and Siravegna, G and Livitz, D and Rhrissorrakrai, K and Martin, EE and Van Seventer, EE and Hanna, M and Slowik, K and Utro, F and Pinto, CJ and Wong, A and Danysh, BP and de la Cruz, FF and Fetter, IJ and Nadres, B and Shahzade, HA and Allen, JN and Blaszkowsky, LS and Clark, JW and Giantonio, B and Murphy, JE and Nipp, RD and Roeland, E and Ryan, DP and Weekes, CD and Kwak, EL and Faris, JE and Wo, JY and Aguet, F and Dey-Guha, I and Hazar-Rethinam, M and Dias-Santagata, D and Ting, DT and Zhu, AX and Hong, TS and Golub, TR and Iafrate, AJ and Adalsteinsson, VA and Bardelli, A and Parida, L and Juric, D and Getz, G and Corcoran, RB
NATURE MEDICINE, ISSN 1078-8956, 09/2019, Volume 25, Issue 9, pp. 1415 - 1415
During cancer therapy, tumor heterogeneity can drive the evolution of multiple tumor subclones harboring unique resistance mechanisms in an individual... 
TARGETED THERAPY | MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | INTRATUMOR HETEROGENEITY | ANTI-EGFR THERAPY | CELL BIOLOGY | GENOMIC LANDSCAPE | EVOLUTION | INHIBITION | COLORECTAL-CANCER | DNA | MUTATIONS | BLOCKADE | Therapy | Sequences | Autopsies | Data acquisition | Case reports | Heterogeneity | Alterations | Biopsy | Autopsy | Lesions | Target acquisition | Deoxyribonucleic acid--DNA | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Concurrent therapy with immune checkpoint inhibitors and TNF alpha blockade in patients with gastrointestinal immune-related adverse events
by Badran, YR and Cohen, JV and Brastianos, PK and Parikh, AR and Hong, TS and Dougan, M
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 08/2019, Volume 7, Issue 1, pp. 226 - 11
Background Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the... 
Checkpoint inhibitor | ANTIBODIES | TNF alpha | CANCER-IMMUNOTHERAPY | IMMUNOLOGY | MELANOMA | Infliximab | ANTI-CTLA-4 | COLITIS | ONCOLOGY | Immune related enterocolitis | Immune related adverse events | CTLA-4 | PD-1 | Patients | Endoscopy | Cancer | TNFα
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy
by Zubiri, Leyre and Allen, Ian M and Taylor, Martin S and Guidon, Amanda C and Chen, Steven T and Schoenfeld, Sara R and Neilan, Tomas G and Sise, Meghan E and Mooradian, Meghan J and Rubin, Krista M and Leaf, Rebecca Karp and Parikh, Aparna R and Faje, Alexander and Gainor, Justin F and Cohen, Justine V and Fintelmann, Florian J and Kohler, Minna J and Dougan, Michael and Reynolds, Kerry L
The Oncologist, ISSN 1083-7159, 11/2019, p. theoncologist.2018-0883
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy
by Parikh, Aparna R and He, Yuting and Hong, Ted S and Corcoran, Ryan B and Clark, Jeff W and Ryan, David P and Zou, Lee and Ting, David T and Catenacci, Daniel V and Chao, Joseph and Fakih, Marwan and Klempner, Samuel J and Ross, Jeffrey S and Frampton, Garrett M and Miller, Vincent A and Ali, Siraj M and Schrock, Alexa B
The Oncologist, ISSN 1083-7159, 10/2019, Volume 24, Issue 10, pp. 1340 - 1347
Background Alterations in the DNA damage response (DDR) pathway confer sensitivity to certain chemotherapies, radiation, and other DNA damage repair targeted... 
Tumor mutational burden | Poly (ADP‐ribose) polymerase | Gastrointestinal cancers | DNA damage response | Immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Concurrent therapy with immune checkpoint inhibitors and TNF[alpha] blockade in patients with gastrointestinal immune-related adverse events
by Badran, Yousef R and Cohen, Justine V and Brastianos, Priscilla K and Parikh, Aparna R and Hong, Theodore S and Dougan, Michael
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 08/2019, Volume 7, Issue 1
Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Research brief convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFv600e colorectal cancer
by Hazar-Rethinam, Mehlika and Kleyman, Marianna and Han, G. Celine and Liu, David and Ahronian, Leanne G and Shahzade, Heather A and Chen, Lifeng and Parikh, Aparna R and Allen, Jill N and Clark, Jeffrey W and Kwak, Eunice L and Faris, Jason E and Murphy, Janet E and Hong, Theodore S and van Seventer, Emily E and Nadres, Brandon and Hong, Catriona B and Gurski, Joseph M and Jessop, Nicholas A and Dias-Santagata, Dora and Iafrate, A. John and van Allen, Eliezer M and Corcoran, Ryan B
Cancer Discovery, ISSN 2159-8274, 04/2018, Volume 8, Issue 4, pp. 417 - 427
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases
by Miller, Cynthia L and Taylor, Martin S and Qadan, Motaz and Deshpande, Vikram and Worthington, Steven and Smalley, Robert and Collura, Chey and Ryan, David P and Allen, Jill N and Blaszkowsky, Lawrence S and Clark, Jeffrey W and Murphy, Janet E and Parikh, Aparna R and Berger, David and Tanabe, Kenneth K and Lillemoe, Keith D and Ferrone, Cristina R
Journal of Gastrointestinal Surgery, ISSN 1091-255X, 11/2017, Volume 21, Issue 11, pp. 1831 - 1840
Optimal margin size when resecting colorectal liver metastases (CRLM) remains unclear, particularly in the setting of perioperative chemotherapy. We evaluated... 
Neoadjuvant chemotherapy | Surgical margin | Colorectal liver metastases | Medicine & Public Health | Surgery | Gastroenterology | SURVIVAL | SURGERY | HEPATECTOMY | DETERMINANT | HEPATIC RESECTION | CANCER | CHEMOTHERAPY | APPRAISAL | IMPACT | Surgicalmargin | ERA | RECURRENCE | GASTROENTEROLOGY & HEPATOLOGY | Multivariate Analysis | Prognosis | Humans | Middle Aged | Male | Liver Neoplasms - therapy | Liver Neoplasms - mortality | Hepatectomy | Fluorouracil - therapeutic use | Colorectal Neoplasms - therapy | Adult | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - therapeutic use | Margins of Excision | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Liver cancer | Colon cancer | Metastasis | Analysis | Adjuvant treatment | Cancer | Chemotherapy | Gastrointestinal surgery
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
by Parikh, Aparna R and Leshchiner, Ignaty and Elagina, Liudmila and Goyal, Lipika and Levovitz, Chaya and Siravegna, Giulia and Livitz, Dimitri and Rhrissorrakrai, Kahn and Martin, Elizabeth E and Van Seventer, Emily E and Hanna, Megan and Slowik, Kara and Utro, Filippo and Pinto, Christopher J and Wong, Alicia and Danysh, Brian P and de la Cruz, Ferran Fece and Fetter, Isobel J and Nadres, Brandon and Shahzade, Heather A and Allen, Jill N and Blaszkowsky, Lawrence S and Clark, Jeffrey W and Giantonio, Bruce and Murphy, Janet E and Nipp, Ryan D and Roeland, Eric and Ryan, David P and Weekes, Colin D and Kwak, Eunice L and Faris, Jason E and Wo, Jennifer Y and Aguet, François and Dey-Guha, Ipsita and Hazar-Rethinam, Mehlika and Dias-Santagata, Dora and Ting, David T and Zhu, Andrew X and Hong, Theodore S and Golub, Todd R and Iafrate, A John and Adalsteinsson, Viktor A and Bardelli, Alberto and Parida, Laxmi and Juric, Dejan and Getz, Gad and Corcoran, Ryan B
Nature medicine, ISSN 1078-8956, 12/2019, Volume 25, Issue 12, pp. 1949 - 1949
An amendment to this paper has been published and can be accessed via a link at the top of the paper. 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Ductal carcinoma in situ: knowledge of associated risks and prognosis among Latina and non-Latina white women
by Parikh, Aparna R and Kaplan, Celia Patricia and Burke, Nancy J and Livaudais-Toman, Jennifer and Hwang, E Shelley and Karliner, Leah S
Breast Cancer Research and Treatment, ISSN 0167-6806, 9/2013, Volume 141, Issue 2, pp. 261 - 268
While not itself life-threatening, ductal carcinoma in situ (DCIS) can progress to invasive disease if untreated, and confers an increased risk of future... 
Ductal carcinoma in situ | Healthcare disparities | Medicine & Public Health | Patient–physician communication | Latino/Hispanic | Language barriers | Oncology | Breast cancer | Patient-physician communication | DIAGNOSIS | INFORMATION | SATISFACTION | DECISION-MAKING | ONCOLOGY | DCIS | BREAST-CANCER PATIENTS | RECURRENCE | OUTCOMES | COMMUNICATION | Prognosis | California - epidemiology | Humans | Middle Aged | Hispanic Americans | European Continental Ancestry Group | Risk | Health Knowledge, Attitudes, Practice | Adult | Female | Registries | Aged | Carcinoma, Intraductal, Noninfiltrating - epidemiology | California - ethnology | Breast Neoplasms - epidemiology | Women | Carcinoma, Ductal | Latino | Patient | Hispanic | physician communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer
by Hazar-Rethinam, Mehlika and Kleyman, Marianna and Han, G. Celine and Liu, David and Ahronian, Leanne G and Shahzade, Heather A and Chen, Lifeng and Parikh, Aparna R and Allen, Jill N and Clark, Jeffrey W and Kwak, Eunice L and Faris, Jason E and Murphy, Janet E and Hong, Theodore S and Van Seventer, Emily E and Nadres, Brandon and Hong, Catriona B and Gurski, Joseph M and Jessop, Nicholas A and Dias-Santagata, Dora and Iafrate, A. John and Van Allen, Eliezer M and Corcoran, Ryan B
Cancer Discovery, ISSN 2159-8274, 04/2018, Volume 8, Issue 4, pp. 417 - 427
Clonal heterogeneity associated with acquired resistance presents a critical therapeutic challenge. Whole-exome sequencing of paired tumor biopsies and... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis
by Kamran, Sophia C and Clark, Jeffrey W and Zheng, Hui and Borger, Darrell R and Blaszkowsky, Lawrence S and Allen, Jill N and Kwak, Eunice L and Wo, Jennifer Y and Parikh, Aparna R and Nipp, Ryan D and Murphy, Janet E and Goyal, Lipika and Zhu, Andrew X and Iafrate, A. John and Corcoran, Ryan B and Ryan, David P and Hong, Theodore S
Cancer Medicine, ISSN 2045-7634, 07/2018, Volume 7, Issue 7, pp. 2934 - 2942
Recent reports demonstrate inferior outcomes associated with primary right‐sided vs left‐sided colorectal tumors in patients with metastatic colorectal cancer... 
overall survival | mutational profiling | colorectal cancer | primary tumor sidedness | EGFR inhibitors | LOCATION | IMPACT | DISTAL | ONCOLOGY | RESECTION | BEVACIZUMAB EFFECTIVENESS | CLINICAL-TRIALS | Genetic aspects | Prognosis | Metastasis | Analysis | Gastrointestinal diseases | Colorectal cancer | Colorectal carcinoma | Mutation | Survival | PTEN protein | Tumors | Metastases | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights